2nd International CytoSorb users meeting shows improved clinical evidence

Berlin. The CytoSorb therapy is safe, easy to handle and able to stabilize the overshooting immune system. These are some of the main results of the second international CytoSorb users meeting, which took place in the first days of October 2015. We thank all 110 participants from 18 countries having joined this platform that enabled users, partners and distributors to exchange their experiences with CytoSorb. Case reports, case series and interim results from several controlled pilot studies were presented and discussed. This was a clear step in CytoSorbents’ continuous strategy to reach a high level of clinical evidence.

Key findings of the symposium include …

 

Key findings of the symposium include:

Safety & Ease of use

  • Treatment has been safe in both critical illnesses and cardiac surgery in more than 8,000 human treatments to date
  • CytoSorb is easy to use without technical complications in a wide range of blood pump systems, including dialysis, continuous renal replacement therapy (CRRT with citrate or heparin anticoagulation) and cardiopulmonary bypass

Early use

Several CytoSorb users showed that the therapy is being used in real-world situations much earlier as an adjunctive therapy to control deadly inflammation and to treat life-threatening illnesses, rather than as a last resort therapy.

Efficiency

  • CytoSorb therapy has contributed to patients’ clinical stability in many ways including:
    • Improving hemodynamic stability
    • Less need for vasopressors
    • Improving metabolic parameters
  • Treatments in liver failure patients have confirmed previous reports of equivalent or superior removal of hepatic toxins from blood, compared with existing liver dialysis therapies. This might be a major new potential in the treatment of viral hepatitis, alcoholic liver disease and others.

Broad indication range

  • CytoSorb has already been applied successfully in a broad range of serious conditions such as severe sepsis, SIRS, septic shock, trauma, rhabdomyolysis, pancreatitis, lung injury, liver and kidney transplantation, liver failure, influenza, cardiac surgery, post-operative inflammation, toxic shock syndrome and many others (e.g. tropical diseases such as Dengue Fever and Scrub Typhus)
  • Preliminary results from two completed cardiac surgery randomized controlled pilot studies from University of Hamburg-Eppendorf and Medical University of Vienna, where CytoSorb was used intra-operatively in a heart-lung machine bypass circuit, as well as data from 142 cardiac surgery patients at University of Cologne, demonstrate:
    • Therapy was well-tolerated and safe without device-related issues, including no heparin removal, no bleeding or coagulation issues, no device set-up concerns
    • Preliminary initial cytokine data show that some cytokines were removed in CytoSorb treated patients compared to control, but overall inflammation in these shorter, lower risk surgeries, was not very high
    • Now that safety has been determined, all three trial sites are interested in extending their treatment experience to complex cardiac surgery, where the risk of inflammation and related complications is much higher
    • These clinical data on safety, ease of use, and feasibility are expected to increase the confidence of the cardiac surgery community to treat a wide range of open heart surgery patients in need with CytoSorb

Presentations

Use of CytoSorb in patients with myoglobinemia

Claus Krenn, Vienna, Austria

Experience with the application of Cytosorb in patients with myoglobinemia.

The immune system and its inflammatory response types

Herwig Gerlach, Berlin, Germany

A comprehensive overview on the mechanisms of the body’s host response, current concepts of the SIRS-MARS-CARS continuum and potential therapeutic avenues to interfere with the disturbed systemic inflammatory response

Cytokin-Adsorption in der Sepsis (in german)

Detlef Kindgen-Milles, Duesseldorf, Germany

A detailed summary on the epidemiology and pathophysiology of sepsis, the rationale for cytokine elimination, conventional techniques and non-specific adsorption approaches with focus on the CytoSorb technology

Levels of immunosuppressive drugs during CytoSorb treatment - In-vitro Study

Steffen Mitzner, Rostock, Germany

Experimental protocol details and first preliminary results on the planned in-vitro study investigating the impact of CytoSorb on drug levels

The impact of CytoSorb on the immune response

John Kellum, Pittsburgh, USA

Most recent evidence on the association between different patterns of cytokines and outcome, CytoSorb’s underlying operating principle and future perspectives for the technology.

The International CytoSorb Registry - Current status

Frank Brunkhorst, Jena, Germany

Overview on the objectives, methods and status of the currently implemented international CytoSorb registry.

Case series of CytoSorb treatments in patients with severe sepsis

Tommaso Laddomada, Zingonia, Italy

Experience using CytoSorb in patients with severe sepsis, septic shock, acute liver failure and rhabdomyolysis

Early application of CytoSorb in septic shock - A 10 vs 10 pilot study

Zsolt Molnar, Szeged, Hungary

Interim analysis results of the first 10 patients included into the ACESS trial.

CytoSorb use in a case of liver failure

Christian Siebers, Munich, Germany

CytoSorb Therapy in a case of sepsis-associated liver dysfunction.

Poster: Role of CytoSorb in optimization of vasopressors and reduction of sepsis scores: A case series

Reshma Tewari, Gurgaon, India

Case series where CytoSorb was successfully used in 10 patients with septic shock

Case series in post-operative cardiac surgery patients

Karl Träger, Ulm, Germany

Interim analysis results on 16 patients treated with CytoSorb for post cardiopulmonary bypass SIRS.

CytoSorb in cardiac surgery with cardiopulmonary bypass (CPB) - A 300 patient three-arm-study

Carolyn Weber, Cologne, Germany

Preliminary interim results of a prospective pilot study using CytoSorb in patients undergoing elective coronary artery bypass grafting (CABG)

Image Gallery